Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
PURPOSE To assess the effects of adjuvant hormone therapy ( AHT ) on survival and disease outcome in women with epithelial ovarian cancer . PATIENTS AND METHODS Participants were premenopausal and postmenopausal women who had been diagnosed with epithelial ovarian cancer ( any International Federation of Gynecology and Obstetrics stage ) 9 or fewer months previously . Ineligible patients included those with deliberately preserved ovarian function , with a history of a hormone-dependent malignancy , or with any contraindications to hormone-replacement therapy . Patients were central ly r and omly assigned in a 1:1 ratio to either AHT for 5 years after r and om assignment or no AHT ( control ) . Main outcome measures were overall survival ( OS ) , defined as time from r and om assignment to death ( any cause ) , and relapse-free survival , defined as time from r and om assignment to relapse or death ( any cause ) . Patients who continued , alive and relapse free , were censored at their last known follow-up . RESULTS A total of 150 patients ( n = 75 , AHT ; n = 75 , control ) were r and omly assigned from 1990 to 1995 from 19 centers in the United Kingdom , Spain , and Hungary ; all patients were included in intention-to-treat analyses . The median follow-up in alive patients is currently 19.1 years . Of the 75 patients with AHT , 53 ( 71 % ) have died compared with 68 ( 91 % ) of 75 patients in the control group . OS was significantly improved in patients who were receiving AHT ( hazard ratio , 0.63 ; 95 % CI , 0.44 to 0.90 ; P = .011 ) . A similar effect was seen for relapse-free survival ( hazard ratio , 0.67 ; 95 % CI , 0.47 to 0.97 ; P = .032 ) . Effects remained after adjustment for known prognostic factors . CONCLUSION These results show that women who have severe menopausal symptoms after ovarian cancer treatment can safely take hormone-replacement therapy , and this may , in fact , infer benefits in terms of OS in addition to known advantages in terms of quality of life
Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .